Enliven Therapeutics (ELVN) Stock Analysis

What Enliven Therapeutics does

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Key metrics

ETFs linked to ELVN

Broad-market and Healthcare sector ETFs an investor holding Enliven Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ELVN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Enliven Therapeutics?

Enliven Therapeutics trades under the ticker ELVN on NASDAQ.

Which exchange is ELVN listed on?

ELVN is listed on NASDAQ.

What sector does Enliven Therapeutics operate in?

Enliven Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ELVN in a portfolio?

PortView shows ELVN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.